



February 1, 2017

Dear Billing/Office Manager,

Moda Health has partnered with Magellan Rx Management (Magellan Rx) to assist you in medical pharmacy management through the provider administered injectable drug program. We are committed to providing our members with access to high-quality healthcare. To ensure our members receive quality and affordable care, we will implement updates to the review and approval processes of certain injectable medications.

Effective April 1, 2017, 4 new medications will be added to the prior authorization list of medications currently in the Magellan Rx program.

Magellan Rx will review your prior authorization requests for the following specialty injectable medications, along with other specialty medications that are already part of the program when administered in:

- an outpatient facility
- a patient’s home
- a physician’s office

Prior Authorization Criteria (effective April 1, 2017)		
Brand name	Generic name	HCPCS code
Imlygic	Talimogene laherparepvec	J9325
Lartuvo	olaratumab	J9999
Krystexxa	pegloticase	J2507
Yondelis	Trabectedin	J9202

Completing prior authorization requests through Magellan Rx will help expedite claims processing and doesn’t require you to submit medical records. If you don’t obtain a prior authorization, your claims may be delayed or denied until we receive the information needed to establish medical necessity.

To begin requesting prior authorizations through the Magellan Rx self-service portal, visit ih.magellanrx.com/ and select “New Access Request-Provider” on the right side of the home page. Find out which medications require prior authorization through Magellan Rx at modahealth.com/medical/injectables.

To learn more about our injectable drug program, please check out our updated Injectable Drug Program FAQ at modahealth.com/pdfs/faq_injectables.pdf.



modahealth.com

PO Box 40384 Portland, Oregon 97240 | 800-852-5195

Claim edit expansion

MagellanRX has partnered with Moda to expand its claim check program to promote appropriate use, safety, and cost effectiveness of medications prescribed to our members. **Beginning April 1, 2017**, Moda will be reviewing claims for appropriate frequency, correct units, and eligible diagnosis codes for the following medications:

Post Service Claims Edits (effective April 1, 2017)		
Brand name	Generic name	HCPCS code
Eligard	leuprolide acetate	J9217
Lupron Depot	leuprolide acetate	J1950
Emend	fosaprepitant	J1453
Faslodex	fulvestrant	J9395
Gemzar	gemcitabine	J9201
Trelstar Depot	triptorelin	J3315
Vantas	histerlin acetate	J9225
Xofigo	radium RA 223 dichloride	A9606
Zoladex	goserelin acetate	J9202

To learn more about our claims edits policy, please visit www.modahealth.com/medical/claim_edits_policy.

Questions?

We appreciate your support in assuring our members receive quality care. If you have any questions, please call our Customer Service team toll-free at 877-605-3229.

Sincerely,

Moda Medical Provider Relations